Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Arsenic and Benzo[A]Pyrene Co-Exposure Effects on Mda-Mb-231 Cell Viability and Migration Publisher



Maleki AS1 ; Ghahremani MH2 ; Shadboorestan A1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Toxicology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
  2. 2. Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

Source: Biological Trace Element Research Published:2024


Abstract

Although humans are frequently exposed to multiple pollutants simultaneously, research on their harmful effects on health has typically focused on studying each pollutant individually. Inorganic arsenic (As) and benzo[a]pyrene (BaP) are well-known pollutants with carcinogenic potential, but their co-exposure effects on breast cancer cell progression remain incompletely understood. This study aimed to assess the combined impact of BaP and As on the viability and migration of MDA-MB-231 cells. The results indicated that even at low levels, both inorganic As (0.01 μM, 0.1 μM, and 1 μM) and BaP (1 μM, 2.5 μM), individually or in combination, enhanced the viability and migration of the cells. However, the cell cycle analysis revealed no significant differences between the control group and the cells exposed to BaP and As. Specifically, exposure to BaP alone or in combination with As (As 0.01 μM + BaP 1 μM) for 24 h led to a significant increase in vimentin gene expression. Interestingly, short-term exposure to As not only did not induce EMT but also modulated the effects of BaP on vimentin gene expression. However, there were no observable changes in the expression of E-cadherin mRNA. Consequently, additional research is required to evaluate the prolonged effects of co-exposure to As and BaP on the initiation of EMT and the progression of breast cancer. © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024.